Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors.

Ma J, Zhang B, Hou J, Peng Y

Diabetes therapy : research, treatment and education of diabetes and related disorders8 Nov 2020Cited by 2 (Europe PMC)

PMID33161492PMCIDPMC7843818DOI10.1007/s13300-020-00955-2PepBankPUB-33161492

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In East Asian patients with T2D receiving dulaglutide, patients with baseline HbA1c of 8.5% or more had greater HbA1c reductions at week 26 than patients below 8.5%.
In plain wordsIn patients taking dulaglutide, higher starting blood sugar accompanied larger reductions than lower starting blood sugar.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction by baseline HbA1c
Study
n = 422
Comparator
Baseline HbA1c below 8.5%
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
At week 26, the reduction of HbA1c and FBG from baseline were similar across subgroups, except that patients with baseline HbA1c ≥ 8.5% had greater HbA1c and FBG reductions than patients with baseline HbA1c < 8.5%.
2 context sentences(design, population, supporting numbers)
Summary · context
This subgroup analysis assessed the efficacy and safety of once weekly dulaglutide 1.5 mg and 0.75 mg in East Asian patients with type 2 diabetes (T2D) stratified by key demographic and baseline characteristics.
Summary · context
A total of 422 East Asian patients with T2D were included in this subgroup analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3316149201
02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In East Asian patients with T2D receiving dulaglutide, patients with baseline HbA1c of 8.5% or more had greater FBG reductions at week 26 than patients below 8.5%.
In plain wordsIn patients taking dulaglutide, higher starting blood sugar accompanied larger fasting sugar reductions than lower starting blood sugar.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFBG reduction by baseline HbA1c
Study
n = 422
Comparator
Baseline HbA1c below 8.5%
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
At week 26, the reduction of HbA1c and FBG from baseline were similar across subgroups, except that patients with baseline HbA1c ≥ 8.5% had greater HbA1c and FBG reductions than patients with baseline HbA1c < 8.5%.
2 context sentences(design, population, supporting numbers)
Summary · context
This subgroup analysis assessed the efficacy and safety of once weekly dulaglutide 1.5 mg and 0.75 mg in East Asian patients with type 2 diabetes (T2D) stratified by key demographic and baseline characteristics.
Summary · context
A total of 422 East Asian patients with T2D were included in this subgroup analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3316149202
03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In East Asian patients with T2D, dulaglutide-associated HbA1c reductions were similar across subgroups other than baseline HbA1c.
In plain wordsIn patients taking dulaglutide, blood sugar reductions were similar across subgroups except those based on starting blood sugar.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHbA1c reduction across other subgroups
Study
n = 422
Comparator
Other demographic and baseline subgroups
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
At week 26, the reduction of HbA1c and FBG from baseline were similar across subgroups, except that patients with baseline HbA1c ≥ 8.5% had greater HbA1c and FBG reductions than patients with baseline HbA1c < 8.5%.
2 context sentences(design, population, supporting numbers)
Summary · context
This subgroup analysis assessed the efficacy and safety of once weekly dulaglutide 1.5 mg and 0.75 mg in East Asian patients with type 2 diabetes (T2D) stratified by key demographic and baseline characteristics.
Summary · context
A total of 422 East Asian patients with T2D were included in this subgroup analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3316149203
04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In East Asian patients with T2D, dulaglutide-associated FBG reductions were similar across subgroups other than baseline HbA1c.
In plain wordsIn patients taking dulaglutide, fasting sugar reductions were similar across subgroups except those based on starting blood sugar.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeFBG reduction across other subgroups
Study
n = 422
Comparator
Other demographic and baseline subgroups
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
At week 26, the reduction of HbA1c and FBG from baseline were similar across subgroups, except that patients with baseline HbA1c ≥ 8.5% had greater HbA1c and FBG reductions than patients with baseline HbA1c < 8.5%.
2 context sentences(design, population, supporting numbers)
Summary · context
This subgroup analysis assessed the efficacy and safety of once weekly dulaglutide 1.5 mg and 0.75 mg in East Asian patients with type 2 diabetes (T2D) stratified by key demographic and baseline characteristics.
Summary · context
A total of 422 East Asian patients with T2D were included in this subgroup analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3316149204
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In East Asian patients taking dulaglutide, HbA1c differed by gender, but the difference was not clinically significant.
In plain wordsIn patients taking dulaglutide, blood sugar differences between genders were not clinically significant.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHbA1c by gender
Study
n = 422
Comparator
Other gender
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Gender analysis showed HbA1c difference that was not clinically significant.
2 context sentences(design, population, supporting numbers)
Summary · context
This subgroup analysis assessed the efficacy and safety of once weekly dulaglutide 1.5 mg and 0.75 mg in East Asian patients with type 2 diabetes (T2D) stratified by key demographic and baseline characteristics.
Summary · context
A total of 422 East Asian patients with T2D were included in this subgroup analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3316149205
06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In East Asian patients taking dulaglutide, weight reductions varied across subgroups without clinically significant differences.
In plain wordsIn patients taking dulaglutide, weight reductions varied across subgroups, but differences were not clinically significant.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeBody weight across subgroups
Study
n = 422
Comparator
Other baseline subgroups
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
The decrease in body weight varied across different subgroups in both dulaglutide doses; however, the difference was not clinically significant.
2 context sentences(design, population, supporting numbers)
Summary · context
This subgroup analysis assessed the efficacy and safety of once weekly dulaglutide 1.5 mg and 0.75 mg in East Asian patients with type 2 diabetes (T2D) stratified by key demographic and baseline characteristics.
Summary · context
A total of 422 East Asian patients with T2D were included in this subgroup analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3316149206
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In East Asian patients taking dulaglutide, gastrointestinal adverse event incidence was generally similar across subgroups.
In plain wordsIn patients taking dulaglutide, digestive side effects were generally similar across subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeGastrointestinal adverse events across subgroups
Study
n = 422
Comparator
Other baseline subgroups
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
The incidence of GI AEs and total hypoglycemia was generally similar across subgroups in both doses.
2 context sentences(design, population, supporting numbers)
Summary · context
This subgroup analysis assessed the efficacy and safety of once weekly dulaglutide 1.5 mg and 0.75 mg in East Asian patients with type 2 diabetes (T2D) stratified by key demographic and baseline characteristics.
Summary · context
A total of 422 East Asian patients with T2D were included in this subgroup analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3316149207
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In East Asian patients taking dulaglutide, total hypoglycemia incidence was generally similar across subgroups.
In plain wordsIn patients taking dulaglutide, low blood sugar events were generally similar across subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHypoglycemia across subgroups
Study
n = 422
Comparator
Other baseline subgroups
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
The incidence of GI AEs and total hypoglycemia was generally similar across subgroups in both doses.
2 context sentences(design, population, supporting numbers)
Summary · context
This subgroup analysis assessed the efficacy and safety of once weekly dulaglutide 1.5 mg and 0.75 mg in East Asian patients with type 2 diabetes (T2D) stratified by key demographic and baseline characteristics.
Summary · context
A total of 422 East Asian patients with T2D were included in this subgroup analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3316149208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01648582

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

Eli Lilly and Companyn = 774Jul 2012 to Dec 2014

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 18 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.